Susan Serrao

January 2023: BioAegis Leverages Gelsolin’s Broad Therapeutic Applicability by Expanding into Multiple Inflammatory Diseases

News /

Company directs clinical effort of its breakthrough therapy to Acute Respiratory Distress Syndrome, for which there are no currently approved treatments. NORTH BRUNSWICK, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma gelsolin, a highly conserved and abundant endogenous human […]

January 2023: BioAegis Leverages Gelsolin’s Broad Therapeutic Applicability by Expanding into Multiple Inflammatory Diseases Read More »

March 2022: BioAegis Therapeutics Completes $22 Million Institutional Sale of Equity in a Non-Brokered Transaction

News /

Fund in Europe leads investment to progress commercialization of breakthrough gelsolin therapy to treat inflammatory and infectious diseases. NORTH BRUNSWICK, N.J., March 22, 2022 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases based on a portfolio built around gelsolin technology, announces the completion of a

March 2022: BioAegis Therapeutics Completes $22 Million Institutional Sale of Equity in a Non-Brokered Transaction Read More »

February 2022: BioAegis Therapeutics Announces Appointment of Two New Corporate Board Members

News /

New board members bring a wealth of financial, strategy and global health expertise.   NORTH BRUNSWICK, N.J., February 17, 2022 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases based on a portfolio built around gelsolin technology, announces the appointment of Dr. Kerry Maguire and Kris

February 2022: BioAegis Therapeutics Announces Appointment of Two New Corporate Board Members Read More »

Kris Vinckier

Leadership /

Kris Vinckier is a Director and Co-Founder of Paradox Investment Management BV, which manages the investment fund, Paradox Investment Network BV, a Private Privak under Belgian Law. Mr. Vinckier is a seasoned executive in the financial and commercial services sector, who currently serves as the Head of Business Strategy Life and Employee Benefits for Vivium,

Kris Vinckier Read More »

Kerry Maguire, DDS, MSPH

Leadership /

Dr. Kerry Maguire is a healthcare executive who most recently served as the Vice-President for Clinical Operations at the Forsyth Institute in Cambridge, MA. As a public health professional, her focus has been on health disparities of vulnerable populations, primarily children and people living with HIV.   Kerry has held faculty roles at Tufts University School

Kerry Maguire, DDS, MSPH Read More »

January 2022: BioAegis’ Novel Host-directed Human Protein for Inflammatory Diseases Geared for Growth in 2022

News /

NORTH BRUNSWICK, N.J., January 24, 2022 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical-stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, reports highlights from its recent shareholder meeting. Highlights Include:  Clinical: Completed second clinical study in the EU and planning US phase 2/3 program

January 2022: BioAegis’ Novel Host-directed Human Protein for Inflammatory Diseases Geared for Growth in 2022 Read More »

October 2021: BioAegis Therapeutics to Present “Conquering Pneumonia and Systemic Inflammation with a Human Protein,” at the MACRO Trends Investor Conference in Belgium

News /

NORTH BRUNSWICK, N.J., October 29, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases based on a portfolio built around gelsolin technology, announces that it was selected to present at the MACRO Trends Investor Conference on November 12, 2021. Co-founders Valerie Ceva, COO, and

October 2021: BioAegis Therapeutics to Present “Conquering Pneumonia and Systemic Inflammation with a Human Protein,” at the MACRO Trends Investor Conference in Belgium Read More »

November 12, 2021: Belgium MACRO Trends Investors Conference

Event /

BioAegis co-founders were selected to present at the upcoming MACRO Trends Investors Conference in Belgium. The presentation, “Conquering Pneumonia and Systemic Inflammation,” will highlight BioAegis’ novel, host-directed treatment. About MACRO Trends MACRO Trends is a Dutch Investment advisory firm centered around a regularly published magazine edited by Brecht Arnaert, a monetary expert at the Rey

November 12, 2021: Belgium MACRO Trends Investors Conference Read More »

September 2021: Researchers Discover Previously Unknown Role of BioAegis’ Therapeutic Gelsolin as Key Signaling Protein Vital for Regulating Immune Cell Inflammatory Response

News /

This biological phenomenon, quorum sensing in macrophages, regulates the transition of cells from inflammatory to healing phenotype.  NORTH BRUNSWICK, N.J., September 28, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases based on a portfolio built around gelsolin technology, announced that a previously unknown

September 2021: Researchers Discover Previously Unknown Role of BioAegis’ Therapeutic Gelsolin as Key Signaling Protein Vital for Regulating Immune Cell Inflammatory Response Read More »

Quorum Sensing by Gelsolin Regulates Programmed Cell Death 4 Expression and a Density-Dependent Phenotype in Macrophages

Publication /

Reshma Kumari Sharma, Binita Goswami, Sukhen Das Mandal, Abhishek Guha, Belinda Willard and Partho Sarothi Ray (2021, August 6). Quorum Sensing by Gelsolin Regulates Programmed Cell Death 4 Expression and a Density-Dependent Phenotype in MacrophagesJ Immunol August 6, 2021, ji2001392; DOI: https://doi.org/10.4049/jimmunol.2001392 Abstract Quorum-sensing mechanisms that sense the density of immune cells at the site of inflammation to initiate inflammation resolution have recently been

Quorum Sensing by Gelsolin Regulates Programmed Cell Death 4 Expression and a Density-Dependent Phenotype in Macrophages Read More »

error: Content is protected !!